Nordazepam

Nordazepam

SCHEMBL78453

O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 2/20 1.00
OPRK1 P41145 2/20 1.00
CNR1 P21554 1/20 1.00
NTSR1 P30989 1/20 1.00
GABRA1 P14867 5/20 0.74
GABRA5 P31644 5/20 0.74
GABRA3 P34903 5/20 0.74
GABRA2 P47869 5/20 0.74
GABRB2 P47870 5/20 0.74
GABRG2 P18507 4/20 0.74
GABRB3 P28472 4/20 0.74
GABRP O00591 3/20 0.74
GABRD O14764 3/20 0.74
GABRB1 P18505 3/20 0.74
GABRA4 P48169 3/20 0.74
GABRE P78334 3/20 0.74
GABRA6 Q16445 3/20 0.74
GABRG1 Q8N1C3 3/20 0.74
GABRG3 Q99928 3/20 0.74
GABRQ Q9UN88 3/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nordazepam SCHEMBL29354494 1.00 PDE4D (1.00) PDE4DOPRK1CNR1NTSR1GABRA1
Nordazepam SCHEMBL8090999 1.00 PDE4D (1.00) PDE4DOPRK1CNR1NTSR1GABRA1
Nordazepam SCHEMBL31000330 1.00 PDE4D (1.00) PDE4DOPRK1CNR1NTSR1GABRA1
Oxazepam SCHEMBL6680438 0.88 LMNA (0.81) PDE4DOPRK1CNR1NTSR1GABRA1
Diazepam SCHEMBL8931438 0.87 GABRA1 (0.79) PDE4DOPRK1CNR1NTSR1GABRA1
Diazepam SCHEMBL6823824 0.87 GABRA1 (0.79) PDE4DOPRK1CNR1NTSR1GABRA1
SCHEMBL10149934 0.86 PDE4D (0.76) PDE4DOPRK1CNR1NTSR1GABRA1
SCHEMBL4371914 0.85 PDE4D (0.74) PDE4DOPRK1CNR1NTSR1GABRA1
SCHEMBL4373660 0.85 PDE4D (0.74) PDE4DOPRK1CNR1NTSR1GABRA1
Delorazepam SCHEMBL32681132 0.85 GABRA1 (1.00) PDE4DOPRK1CNR1NTSR1GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 4757 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3436000-B1 USE OF CANNABINOIDS IN THE TREATMENT OF STURGE WEBER SYNDROME JAZZ PHARMACEUTICALS RESEARCH UK LTD (GB) 2025-07-16 EP claimed
US-20250179064-A1 BENZOQUINOLONE INHIBITORS OF VMAT2 AUSPEX PHARMACEUTICALS LLC 2025-06-05 US claimed
US-20250152591-A1 TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS KURA ONCOLOGY INC (US) 2025-05-15 US claimed
EP-3592350-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING METYRAPONE AND OXAZEPAM AND USES THEREOF EMBERA NEUROTHERAPEUTICS INC (US) 2025-03-05 EP claimed
EP-4472637-A1 TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS Kura Oncology, Inc. (US) 2024-12-11 EP claimed
US-12133922-B2 Abuse resistant capsule R.P. SCHERER TECHNOLOGIES, LLC (US) 2024-11-05 US claimed
US-20240353434-A1 METHOD FOR SIMULTANEOUS AND EFFICIENT DETECTION OF RESIDUES OF 36 ANTIDEPRESSANTS IN SLUDGES Institute of Microbiology, Guangdong Academy of Sciences (Guangdong Detection Center of Microbiology (CN) 2024-10-24 US claimed
US-20240350428-A1 USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE 2024-10-24 US claimed
CN-118773221-A CYP2C19 gene mutant nucleic acid segment and application thereof 中南大学湘雅三医院 2024-10-15 CN claimed
EP-4422607-A1 ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT Aquestive Therapeutics, Inc. (US) 2024-09-04 EP claimed
WO-2002006826-A1 SINGLE-PATIENT DRUG TRIALS USED WITH ACCUMULATED DATABASE OPT-E-SCRIP, INC. (US) 2002-01-24 WO claimed
WO-2002000221-A1 ENHANCED BRAIN FUNCTION BY GABA-ERGIC STIMULATION UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2002-01-03 WO claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
EP-1067942-A1 HIGH-ENERGY CYCLODEXTRIN COMPLEXES Cyclops, EHF. (IS) 2001-01-17 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
WO-1999061014-A2 COMPOSITIONS AND METHODS EMPLOYING R(-) FLUOXETINE AND OTHER ACTIVE INGREDIENTS SEPRACOR INC. (US) 1999-12-02 WO claimed
WO-1999042111-A1 HIGH-ENERGY CYCLODEXTRIN COMPLEXES CYCLOPS, EHF. (IS) 1999-08-26 WO claimed
US-5308768-A Detection of cortisols, cortisone and corticosterone WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1994-05-03 US claimed
US-4557934-A ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE THE PROCTER & GAMBLE COMPANY (US) 1985-12-10 US claimed